摘要
目的观察临床治疗高血压性肾功能衰竭过程中采用厄贝沙坦的疗效。方法 60例高血压性肾功能衰竭患者,随机分为观察组和对照组,每组30例。对照组实施常规治疗,观察组在对照组基础上加用厄贝沙坦治疗,对比两组临床疗效、治疗前后血压及治疗后肾功能改善情况。结果观察组总有效率96.67%高于对照组的80.00%,差异具有统计学意义(P<0.05)。治疗后,观察组的收缩压(SBP)为(112.12±7.23) mm Hg(1 mm Hg=0.133 kPa)和舒张压(DBP)为(71.02±3.01) mm Hg低于对照组的(141.25±9.05)、(89.10±4.02) mm Hg,差异具有统计学意义(P<0.05);治疗后,观察组血清尿素氮(BUN)为(6.19±0.27)mmol/L、肌酐(SCr)为(76.89±2.41)μmol/L、内生肌酐清除率(CCr)为(70.01±4.12)ml/min、冠状动脉血流储备(CFR)为(102.34±4.53)ml/min,血尿酸(UA)为(329.98±12.78)μmol/L、血清β_2-微球蛋白(β_2-MG)为(2.09±0.41)mg/L,优于对照组的(8.16±0.39)mmol/L、(92.86±2.95)μmol/L、(48.01±3.92)ml/min、(78.49±3.79)ml/min、(507.52±15.72)μmol/L和(3.59±0.72)mg/L,差异具有统计学意义(P<0.05)。结论临床在采用硝苯地平和美托洛尔治疗高血压性肾功能衰竭的基础上加用厄贝沙坦的疗效显著,可有效提升临床治疗总有效率,显著改善患者的血压水平、促进患者肾功能的快速恢复,临床应用价值显著。
Objective To observe the efficacy of irbesartan in the treatment of hypertensive renal failure. Methods A total of 60 hypertensive renal failure patients were randomly divided into observation group and control group, with 30 cases in each group. The control group received conventional therapy, and the observation group received irbesartan for treatment on the basis of the control group. Comparison were made on clinical efficacy, blood pressure before and after treatment, and renal fuction improvement after treatment in two groups. Results The observation group had higher total effective rate as 96.67% than 80.00% in the control group, and their difference was statistically significant(P<0.05). After treatment, the observation group had lower systolic blood pressure(SBP) as(112.12±7.23) mm Hg(1 mm Hg=0.133 kPa) and diastolic blood pressure(DBP)as(71.02±3.01) mm Hg than(141.25±9.05) mm Hg and DBP as(89.10±4.02) mm Hg in the control group. Their difference was statistically significant(P<0.05). After treatment, the observation group had better blood urea nitrogen(BUN) as(6.19±0.27) mmol/L, serum creatinine(SCr) as(76.89±2.41)μmol/L, endogenous creatinine clearance rate(CCr) as(70.01±4.12) ml/min, coronary flow reserve(CFR) as(102.34±4.53) ml/min, blood uric acid(UA)as(329.98±12.78)μmol/L,β2-microglobulin(β2-MG) as(2.09±0.41) mg/L than(8.16±0.39) mmol/L,(92.86±2.95)μmol/L,(48.01±3.92) ml/min,(78.49±3.79) ml/min,(507.52±15.72)μmol/L and(3.59±0.72) mg/L. Their difference was statistically significant(P<0.05). Conclusion Irbesartan shows remarkable efficacy in treating hypertensive renal failure on the basis of nifedipine and metoprolol, and it can significantly improve the blood pressure level of patients, and promote the rapid recovery of renal function. The clinical application value is significant.
作者
陈英
袁红英
CHEN Ying;YUAN Hongying(Weifang Fangzi District People' s Hospital,Weifang 261200,China)
出处
《中国实用医药》
2019年第14期100-101,共2页
China Practical Medicine
关键词
厄贝沙坦
高血压
肾功能衰竭
应用效果
Irbesartan
Hypertensive
Renal failure
Application effect
